Drug Profile

PC 786

Alternative Names: PC-786

Latest Information Update: 27 Oct 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pulmocide
Class Amides; Antivirals; Benzazepines; Pyridines; Small molecules; Spiro compounds; Thiophenes
Mechanism of Action RNA-dependent RNA polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Respiratory syncytial virus infections

Most Recent Events

27 Oct 2020 Discontinued - Phase-II for Respiratory syncytial virus infections in United Kingdom (Inhalation) (Pulmocide's pipeline, October 2020)
01 May 2019 Pulmocide terminates the phase II TreatRSV1 trial in Respiratory syncytial virus infections in United Kingdom (Inhalation) (NCT03715023)
25 Jan 2019 Chemical structure information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com